China seen as the next big growth area for biotechs Biogen and Amgen


SunTrust initiated coverage on Biogen and Amgen on Tuesday, rating each stock as a buy based on solid drug pipelines and growth opportunities in China.

SunTrust's bullish thesis on Biogen is based on the company's Alzheimer's drug aducanumab. In October the company said it was once again seeking regulatory approval for the drug, which would be the first of its kind in the billion-dollar Alzheimer's market.

SunTrust also points to Biogen's strength in biosimilars, which are generic versions of biologic medicines used to treat illnesses like cancer and autoimmune diseases, as well as growth opportunities in China.

More In Pro News and Analysis

CNBC ProGoldman Sachs names China's next billion-dollar brands and picks the ‘hottest’ stocks
CNBC ProEvercore ISI just launched coverage on the clean energy sector. These are the firm's top picks
CNBC ProWhy Dan Niles likes Facebook and Alphabet as U.S. economy recovers from Covid